> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Dr. Reddy’s Duvvada Facility Cited by FDA Again
- URL: https://www.fdaweb.com/dr-reddys-duvvada-facility-cited-by-fda-again/
- Published: 2017-03-09T12:00:00.000Z
- Updated: 2026-09-14T22:10:46.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138161

The Dr. Reddy’s oncology drug formulation manufacturing facility at Duvvada, Visakhapatnam, India, that was one of the facilities named in a 2015 [Warning Letter](fdaweb.com/login.php?sa=v&aid=D5133888&searchWords=dr.%20reddy&cate=S&stid=%241%244S0.5V3.%24ut2zt57QqJUbHf2622ksy1), has been issued an FDA-483 containing 13 inspection observations, according to a company [statement](http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/6C55917C%5F771B%5F442E%5FA3F2%5F819C4D902562%5F112314.pdf?ref=fdaweb.com) to India financial regulators and the New York Stock Exchange. The statement says the company is addressing the inspection observations but provides no details.

Last month, FDA [issued](https://www.fdaweb.com/agency-cites-dr-reddys-again-after-inspection/) a three-observation FDA-483 for Dr. Reddy’s Miryalaguda active pharmaceutical ingredients plant in Telangana, India. That facility was also included in the 2015 Warning Letter.